Strategic development of antihumoral therapies provides a means for achieving enhanced therapeutic results. The basic immunobiology of humora alloresponses is currently adequate to allow development of new therapies. Plasma cell targeted therapy is one example of new treatment paradigms based on known immunobiology. This talk will describe the biologic basis for plasma cell targeting in general, and for proteasome inhibition in particular.
What You'll Take Away from His Talk:
Substantial evidence exists from basic research that plasma cell targeted therapy may provide a viable means for mitigating humoral alloresponses.
Initial evidence from clinical experiences with proteasome inhibition indicate that proteasome inhibitor-based regimens offer therapeutic potential.
Substantial opportunities exist for enhancing proteasome inhibitor therapy via combinatorial strategies.